News
-
POSITION PAPER | The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
The Thalassaemia International Federation (TIF) is pleased to share its newly published Position Paper, titled “Advanced Therapy Medicinal Products (ATMPs).” This comprehensive document delves into the challenges eligible patients face…
Read More » -
INFOGRAPHICS | Mapping Blood Use in Patients with Thalassaemia Across the EU
Have You Ever Wondered How Much Blood is Consumed by Patients with Thalassaemia in EU Countries? To answer this question, the Thalassaemia International Federation (TIF) collected data from 15 EU…
Read More » -
EXCLUSIVE WEBINAR | Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders
📌 Webinar Title: Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders – The Transfusion Dependent Thalassaemia (TDT) Perspective 📌 Date & Time: 5 December 2024 / 13:30…
Read More » -
EDUCATIONAL WEBINAR FOR PATIENTS ON IRON OVERLOAD AND MONITORING | 21 November 2024
📌 Webinar Title: Webinar for Patients on Iron Overload and Iron Monitoring 📌 Date & Time: Thursday, November 21, 13:00 New York / 14:00 Rio de Janeiro This webinar…
Read More » -
SICKLE CELL DISEASE | FDA Grants Orphan Drug Designation to AND017
Announced by KIND Pharmaceuticals on October 25, 2024, ODD is granted to a drug or biological product to prevent, diagnose, or treat a rare disease or condition that affects fewer…
Read More » -
TIF STUDY | Desferioxamine Usage Survey
Desferioxamine is crucial in managing iron overload for many patients with thalassaemia and related blood conditions. Recently, the Thalassaemia International Federation (TIF) has received growing reports of shortages in Desferioxamine,…
Read More » -
-
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm Autoimmune Hemolytic Anemia (wAIHA) occurs when the body’s immune system mistakenly produces antibodies that attack and destroy its own red blood cells. In this particular case, the patient presented…
Read More » -
WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta
Oxbryta, which was designed to treat sickle cell disease, has been a crucial medication for patients with mild-to-moderate symptoms. Approved in the US under an accelerated process in 2019 and…
Read More » -
APLASTIC ANEMIA | Hetrombopag Achieves Significant Hematological Responses in Newly Diagnosed Patients
In this study, newly diagnosed patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA) were initially treated with either a combination of cyclosporin A (CsA) and hetrombopag (HETROM+CsA group) or CsA alone…
Read More »